Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

Exelixis (EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER.The recent data readout from studies on zanzalintinib has been positive.In June 2025, EXEL announced...